Skip to content
Subscriber Only
Business
Prognosis

Johnson & Johnson, AstraZeneca Trials to Resume, Rejoining Vaccine Race

  • Two top contenders to restart trials paused after illnesses
  • Companies in late-stage research as virus spread worsens
Video player cover image
Vaccine Will Be 'Moderately Effective': Vanderbilt's Schaffner
Updated on

AstraZeneca Plc and Johnson & Johnson plan to resume Covid-19 vaccine clinical trials that had been halted by U.S. regulators, putting research into two of the leading candidates for a coronavirus inoculation back on track.

Johnson & Johnson said in a statement Friday it is preparing to resume recruitment in a late-stage trial of its vaccine after consultation with the U.S. Food and Drug Administration. An independent data safety monitoring board recommended the trial continue. The study was paused earlier this month after a patient became sick, but the company said no clear cause of the illness had been identified.